Pancreatic Safety of Sitagliptin in the TECOS Study

201659 citationsJournal Articlebronze Open Access

Authors

John B. Buse · University of North Carolina at Chapel Hill

M. Angelyn Bethel · University of Oxford

Jennifer B. Green · Duke University

Susanna R. Stevens · Clinical Research Institute

Yuliya Lokhnygina · Clinical Research Institute

Pablo Aschner · Pontificia Universidad Javeriana

Carlos Raffo Grado

Abstract

Pancreatitis and pancreatic cancer were uncommon events with rates that were not statistically significantly different between the sitagliptin and placebo groups, although numerically more sitagliptin participants developed pancreatitis and fewer developed pancreatic cancer. Meta-analysis suggests a small absolute increased risk for pancreatitis with DPP-4i therapy.

Topics & Keywords

Diabetes Treatment and Management Neuroendocrine Tumor Research Advances Peptidase Inhibition and Analysis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Diabetes Care

Volume 40, Issue 2, pp. 164-170

DOI: 10.2337/dc15-2780

Field-Weighted Citation Impact: 6.51